@inproceedings{inproceedings, title  = {{Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis.}},

 url = {{}},

 year = {{2002}},

 month = {{12}},

 author = {{Coleman RE and Rosen LS and Gordon D and Major P and Kaminski M and Apffelstaedt J and Howell A and Chen BL and Seaman JJ}},

 volume = {{76}},

 journal = {{BREAST CANCER RESEARCH AND TREATMENT}},

 pages = {{S95-S95}},

 note = {{Accessed on 2025/10/10}}}